PT  - JOURNAL ARTICLE
AU  - Gonzalez Lopez Ledesma, María M.
AU  - Sanchez, Lautaro
AU  - Ojeda, Diego S.
AU  - Rouco, Santiago Oviedo
AU  - Rossi, Andres H.
AU  - Varese, Augusto
AU  - Mazzitelli, Ignacio
AU  - Pascuale, Carla A.
AU  - Miglietta, Esteban A.
AU  - Rodríguez, Pamela E.
AU  - Pallarés, Horacio M.
AU  - Costa Navarro, Guadalupe S.
AU  - Caramelo, Julio J.
AU  - Rothlauf, Paul W
AU  - Liu, Zhuoming
AU  - Bloyet, Louis-Marie
AU  - Pontelli, Marjorie Cornejo
AU  - Rasetto, Natali B.
AU  - Wenker, Shirley D.
AU  - Ramis, Lila Y.
AU  - Bialer, Magalí G.
AU  - Jose de Leone, María
AU  - Hernando, C. Esteban
AU  - Bianchimano, Luciana
AU  - Rios, Antonella
AU  - Treffinger Cienfuegos, María Soledad
AU  - Rodriguez García, Diana R.
AU  - Longueira, Yesica
AU  - Laufer, Natalia
AU  - Alvarez, Diego
AU  - Ceballos, Ana
AU  - Ochoa, Valeria
AU  - Monzani, Cecilia
AU  - Turk, Gariela
AU  - Salvatori, Melina
AU  - Carradori, Jorge
AU  - Prost, Katherine
AU  - Rima, Alejandra
AU  - Varela, Claudia
AU  - Ercole, Regina
AU  - Toro, Rosana I.
AU  - Gutierrez, Sebastian
AU  - Zubieta, Martín
AU  - Acuña, Dolores
AU  - Nabaes Jodar, Mercedes S.
AU  - Torres, Carolina
AU  - Mojsiejczuk, Laura
AU  - Viegas, Mariana
AU  - Velazquez, Pilar
AU  - Testa, Clarisa
AU  - Kreplak, Nicolas
AU  - Yanovsky, Marcelo
AU  - Whelan, Sean
AU  - Geffner, Jorge
AU  - Pifano, Marina
AU  - Gamarnik, Andrea V.
TI  - Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape over Time
AID  - 10.1101/2021.08.22.21262186
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.08.22.21262186
4099  - http://medrxiv.org/content/early/2021/10/25/2021.08.22.21262186.short
4100  - http://medrxiv.org/content/early/2021/10/25/2021.08.22.21262186.full
AB  - Recent studies have shown a temporal increase in the neutralizing antibody potency and breadth to SARS-CoV-2 variants in coronavirus disease 2019 (COVID-19) convalescent individuals. Here, we examined longitudinal antibody responses and viral neutralizing capacity to the B.1 lineage virus (Wuhan related), to variants of concern (VOCs: Alpha, Beta, Gamma, and Delta) and a local variant of interest (VOI: Lambda) in volunteers receiving the Sputnik V vaccine in Argentina. A collection of 472 serum samples obtained between January and September 2021 was used. The analysis indicates that while anti-spike IgG levels significantly wane over time, the neutralizing capacity to the first-wave linages of SARS-CoV-2 and VOC are maintained within four months of vaccination. In addition, an improved antibody cross-neutralizing ability to circulating variants of concern (Beta, Gamma and Delta) was observed over time of vaccination. The viral variants that displayed higher escape to neutralizing antibodies with respect to the original virus (Beta and Gamma variants) were the ones showing the largest increase in susceptibility to neutralization over time after vaccination. Our observations indicate that serum neutralizing antibodies are maintained for at least four month and show a reduction of VOC escape over time of vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by NIH (NIAID) R01.AI095175 and PICT-2017-1717, PICT- 2015-2555 to AVG and by the National Ministry of Science Technology and Innovation or Argentina.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the central ethics committee of Buenos Aires province, Argentina. File number: IF-2021-09238265-GDEBA-CECMSALGP. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available.